Researchers at the Icahn School of Medicine at Mount Sinai have identified LRRK2 gene mutations as a common element in both inflammatory bowel disease (IBD), an umbrella name for disorders marked by prolonged inflammation of the digestive tract, and Parkinson’s disease. The study also identified genes involved in inflammation…
News
Low to moderate doses of CAP-003, a gene therapy in the pipeline from Capsida Biotherapeutics, increased levels of glucocerebrosidase (GCase), an enzyme that’s missing or faulty in some people with Parkinson’s disease, in the brain of nonhuman primates. Given as a one-time infusion into the vein, or intravenously,…
Support networks are important for people with Parkinson’s disease, and patients in rural areas don’t always have access to information that would help improve their lives, Central Michigan University researchers said. The researchers are wrapping up a year-long project studying whether creating support networks in underserved U.S. rural communities…
NE3107, now known as bezisterim, eased both motor and nonmotor symptoms when used in combination with a standard carbidopa/levodopa regimen in people with Parkinson’s disease, study data showed. Twice-daily dosing with the anti-inflammatory small molecule being developed by BioVie resulted in better motor function upon waking, more restful…
Genetic variations along with exposure to environmental factors, such as pesticides, may increase Parkinson’s disease in a sex-dependent manner, a study of French farmworkers suggests. “Most cases of Parkinson’s disease don’t arise from a single factor, but rather … a combination of a person’s genes, lifestyle, and what they’re…
Dosing has begun in a Phase 1 clinical trial evaluating the safety and efficacy of IRL757, an oral candidate for apathy treatment in people with Parkinson’s disease and other neurological conditions. Irlab Therapeutics, the therapy’s developer, recently announced the trial’s launch following approval by the Swedish Medical…
The U.S. Senate has joined the House of Representatives in approving The National Plan to End Parkinson’s Act, the first piece of federal legislation dedicated to ending Parkinson’s disease. Celebrated by the Michael J. Fox Foundation for Parkinson’s Research (MJFF), the bill now will be sent to…
Physical exercise may reduce the risk of developing Parkinson’s disease, as well as effectively control patients’ symptoms, according to a review analysis by researchers in Europe. Moreover, some studies suggest that exercise might be a potential disease-modifying treatment, working to slow disease progression and stabilizing, or even reducing, the…
In a first-of-its-kind development, a team of scientists created a lab model of the blood-brain barrier (BBB) surrounding the brain. The new model represents “a game-changing technology with broad implications for neuroscience, drug discovery, and personalized medicine,” Ziyuan Guo, PhD, assistant professor at the University of Cincinnati department of pediatrics…
The European Inventor Award 2024 has named as finalists a French husband-and-wife team of scientists who developed a dosing pump that allows for direct delivery of dopamine to the brain in people with Parkinson’s disease. The use of dopamine is expected to help reduce symptoms and so-called off…
Recent Posts
- FDA grants advanced therapy status to Parkinson’s cell treatment
- Experimental drug BT-267 shows promise in Parkinson’s study
- Saying goodbye to my doctors leaves me sad, but grateful
- Deep brain stimulation was a lifesaver for my husband with Parkinson’s
- Me and Mary Jane: My one experience trying marijuana for Parkinson’s